Translated from our German original by AI. The German text was researched, written, and edited by the Psychedelia Foundation team and remains the authoritative version.
Psilocybin-containing mushrooms are the subject of both ecological and pharmacological research. Alongside their traditional use as psychoactive substances, scientists are interested in questions such as why the fungi produce psilocybin at all and what significance the compound has for their evolution.
The psychoactive use of certain mushrooms is documented above all in indigenous traditions of Central America. Responsible for the psychedelic effect is not psilocybin itself, but primarily psilocin, its dephosphorylation product formed in the body. This acts mainly at the serotonin 5-HT2A receptor.
The emergence of psilocybin biosynthesis is also remarkable in evolutionary terms. Studies show that fungi apparently developed the ability to produce psilocybin at least twice independently of one another, recruiting different enzymes and biosynthetic pathways in the process. More recent work confirms that the capacity for psilocybin production arose several times over the course of fungal evolution.
What function psilocybin serves within the fungus itself, by contrast, is still not conclusively established. One hypothesis under discussion concerns protection against being eaten: when fungal tissue is damaged, psilocin can react to form oligomeric or polymeric compounds. These have chemical properties reminiscent of plant polyphenols and tannins. The blue compounds that arise in the process may serve to deter predators. This function remains a hypothesis, however, and not a conclusively demonstrated biological purpose.
For humans, the psychoactive effect is what stands at the center. Psilocybin can produce intense changes in perception, thinking, and emotion. At high or uncontrolled doses in particular, and under unfavorable conditions, severe anxiety, panic, and transient psychotic symptoms can occur.
In parallel, researchers are investigating whether the pharmacological effects of psilocybin can be used therapeutically. Preclinical studies and initial findings in human cells suggest that psilocin can influence processes of neuronal plasticity. Activation of 5-HT2A receptors plays an important role here, and BDNF/TrkB-mediated mechanisms are among those also under discussion. Which of these processes are actually decisive for therapeutic effects in humans has not yet been conclusively established.
Psilocybin therefore continues to be studied in clinical trials for various mental illnesses. What is at stake there is not only the pharmacological effect of the substance, but its application within a controlled therapeutic setting. The research remains at a developmental stage, and no general therapeutic efficacy across all mental illnesses can be derived from the findings so far.
Research on “magic mushrooms” thus brings together several distinct questions: from the repeated evolutionary emergence of psilocybin biosynthesis, through a possible ecological function of the fungal compounds, to the neurobiological effects and potential medical use of psilocybin.
